Biobot Surgical, a robotic-assisted percutaneous surgical systems company headquartered in Singapore, has signed an MoU with BEBIG Medical, a global provider of radiotherapy products and a brachytherapy leader based in Europe to work together to provide a robotic-guided high dose rate (HDR) brachytherapy solution for prostate cancer treatment.

Biobot Surgical developed the iSR'obot Mona Lisa 2.0, a robotic-assisted percutaneous surgical system that allows clinicians to plan and position needles during image-guided diagnostic and interventional prostate procedures.

Using the iSR'obot Mona Lisa 2.0 for HDR brachytherapy, it automatically guides the needle insertion by a clinician to within 1.0mm accuracy of the targeted needle position for treatment. The robotic arm allows flexibility of angulated needle trajectory for an optimal treatment plan and avoids critical anatomical structures.

"The future trend of medical device technology was moving toward digitalization, automation and artificial intelligence. The joint partnership is a vivid display of these orientations to achieve clinical excellence," said George Chan, Chairman and CEO of BEBIG Medical.